Form 8-K - Current report:
SEC Accession No. 0001493152-23-012566
Filing Date
2023-04-17
Accepted
2023-04-17 16:50:42
Documents
23
Period of Report
2023-04-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43994
2 ex99-1.htm EX-99.1 34685
3 ex99-2.htm EX-99.2 847
4 ex99-3.htm EX-99.3 847
5 ex99-4.htm EX-99.4 870
6 ex99-5.htm EX-99.5 848
7 ex99-1_001.jpg GRAPHIC 4508
8 ex99-2_01.jpg GRAPHIC 1617750
9 ex99-3_01.jpg GRAPHIC 1846901
10 ex99-4_001.jpg GRAPHIC 890998
11 ex99-5_001.jpg GRAPHIC 830933
  Complete submission text file 0001493152-23-012566.txt   7460665

Data Files

Seq Description Document Type Size
12 XBRL SCHEMA FILE bct-20230417.xsd EX-101.SCH 3681
13 XBRL DEFINITION FILE bct-20230417_def.xml EX-101.DEF 26582
14 XBRL LABEL FILE bct-20230417_lab.xml EX-101.LAB 36619
15 XBRL PRESENTATION FILE bct-20230417_pre.xml EX-101.PRE 25206
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5488
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 23824509
SIC: 2834 Pharmaceutical Preparations